Healthcare Industry News: Hummingbird
News Release - July 23, 2012
InnerSpace Neuro Announces Launch of New, Tunneled TBI Catheter, Abstract PresentationPHOENIX--(Healthcare Sales & Marketing Network)--InnerSpace Neuro, Inc., developer of the Hummingbird family of products used to treat Traumatic Brain Injury (TBI), today reported that an abstract featuring its Hummingbird SynergyDuo Ventricular Catheter is being presented at the Neurotrauma 2012 meeting in Phoenix, Arizona. The company also announced launch of its new Tunneled Ventricular Catheter.
The abstract, authored by Dr. Howard Yonas, M.D., et al, from the University of New Mexico, showed that brain access provided by the SynergyDuo Ventricular is critical to ensuring a fixed spatial relationship between the probes with consistent placement in the brain’s deep frontal white matter. Over 209 procedures were part of the clinical study; 65 of those procedures used the SynergyDuo Ventricular Catheter.
“Parameter integration, consistency in catheter placement, and fixed spatial relationships of brain probes are critical elements in caring for TBI patients,” said Dr. Yonas.
The Hummingbird Tunneled Ventricular Catheter, launched at the Neurotrauma meeting, is the first-ever tunneled ventricular catheter that provides dedicated ICP monitoring with continuous ventricular drainage. The company’s patented AirPulse ICP technology eliminates the need for a transducer on the external ventricular drainage (EVD) mount, thereby avoiding priming, de-bubbling, breaking sterility to re-zero, and ICP leveling of fluid-filled systems.
“The Hummingbird Tunneled Ventricular Catheter provides critical treatment for TBI,” said Ben Bobo, General Manager of InnerSpace Neuro, Inc. “The dedicated ICP monitoring and continuous EVD drainage eliminates the need to monitor just one variable at a time, which provides both flexibility and simplicity when treating these patients.”
InnerSpace Neuro, Inc., based in Tustin, California, has developed a family of next-generation integrated access products for neuromonitoring of patients after a traumatic brain injury. InnerSpace Neuro’s 510(k) approved products enable multiparameter monitoring and address many of the limitations of traditional intracranial pressure monitoring technologies, without the need for a dedicated capital equipment monitor. The family of 510(k) approved products are based on the proprietary AirPulse pressure sensor technology.
For more information, please contact Ben Bobo at (714) 654-2367 or visit our website at www.innerspacemedical.com
Source: InnerSpace Neuro
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.